Iodinated nitroimidazoles as radiosensitizers

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2145-2151

  Krause, Werner ^a   Jordan, Andreas ^b   Scholz, Regina ^b   Jimenez, José Luis Martin ^c,d  

^a BAYER PHARMA AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Justesa Imagen SA   (Spain)

^d Center of Biomedical Nanotechnology (CBN)   (Germany)

Author keywords

Nitroimidazole; Radiosensitizer

Indexed keywords

IODINE; METRONIDAZOLE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; ZK 188790; ZK 188970; ZK 236039; ZK 852714;

ARTICLE; CELL HYPOXIA; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FILM DOSIMETER; HUMAN; HUMAN CELL; HYDROPHILICITY; OXYGEN ENHANCEMENT RATIO; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY;

ADENOCARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; HYDROCARBONS, IODINATED; NITROIMIDAZOLES; RADIATION-SENSITIZING AGENTS;

EID: 21344470638     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hennequin C and Maylin C: Continuous radiosensitizing chemotherapy. Pathol Biol (Paris) 47(3): 279-281, 1999.
2. Herscher LL and Cook J: Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol 11(3): 183-186, 1999.
3. Kinsella TJ: Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers. Semin Oncol 19(3): 41-47, 1992.
4. McGinn CJ and Kinsella TJ: The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 19(4): 21-28, 1992.
5. McGinn CJ and Kinsella TJ: The clinical rationale for S-phase radiosensitization in human tumors. Curr Probl Cancer 17(5): 273-321, 1993.
6. Khattab J and Urba SG: Chemotherapy in head and neck cancer. Overview of newer agents. Hematol Oncol Clin North Am 13(4): 753-768, 1999.
7. Acharya DK: Role of metronidazole in radiation therapy (a review of 717 cancer cases). Indian J Med Sci 48(5): 111-116, 1994.
8. Kasai S, Nagasawa H, Yamashita M, Masui M, Kuwasaka H, Oshodani T et al: New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg Med Chem 9(2): 453-464, 2001.
9. Abou-Bedair FA, Hori H, Nagasawa H, Uto Y, Abu-Zeid M and Inayama S: Comparison of hypoxic cell radiosensitizers, KIN-804, KIN-844, KIN-806 and TX-1877, on brain and liver metabolizing capacities in mice bearing Ehrlich ascites carcinoma. Biol Pharm Bull 25(5): 591-596, 2002.
10. Shimamura M, Nagasawa H, Ashino H, Yamamoto Y, Hazato T, Uto Y et al: A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors. Br J Cancer 88(2): 307-313, 2003.
11. Jin CZ, Nagasawa H, Shimamura M, Uto Y, Inayama S, Takeuchi Y et al: Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers. Bioorg Med Chem 12(18): 4917-4927, 2004.
12. Papadopoulou MV, Rosenzweig HS and Bloomer WD: Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin. Bioorg Med Chem Lett 14(6): 1519-1522, 2004.
13. Puck TT and Marcus PI: A rapid method for viable cell titration and clonic production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 41: 432-437, 1955.
14. Roizin-Towle L, Hall EJ and Pirro JP: Oxygen dependence for chemosensitization by misonidazole. Br J Cancer 54(6): 919-924, 1986.
15. Stratford IJ, Adams GE, Hardy C, Hoe S, O'Neill P and Sheldon PW: Thiol reactive nitroimidazoles: radiosensitization studies in vitro and in vivo. Int J Radiat Biol Relat Stud Phys Chem Med 46(6): 731-745, 1984.
16. Gupta RP, Larroquette CA, Agrawal KC, Grodkowski J and Neta P: Potential radiosensitizing agents. 7. 4(5)-Iodo-5(4)-nitroimidazole derivatives. J Med Chem 28(8): 987-991, 1985.
17. Wardman P and Clarke ED: One-electron reduction potentials of substituted nitroimidazoles measured by pulse radiolysis. J Chem Soc Faraday Trans 172(6): 1377-1390, 1976.
18. Agrawal KC, Millar BC and Neta P: Radiosensitization of hypoxic mammalian cells by dinitroimidazoles. Radiat Res 78(3): 532-541, 1979.
19. Ma H, Hardy CR and O'Neill P: Formation of halide-ions on one-electron reduction of halogenated nitroimidazoles in aqueous solution. A radiolytic study. Int J Radiat Biol Relat Stud Phys Chem Med 41(2): 151-160, 1982.
20. Meisel D and Neta P: One-electron redoc potentials of nitro compounds and radiosensitizers. Correlation with spin densities of their radical anions. J Am Chem Soc 97(18): 5198-5203, 1975.
21. Krause W: Tailored contrast agents for angiography and intervention. In: Radiology of Peripheral Vascular Diseases (Zeitler E, ed.) Springer-Verlag, Berlin, Heidelberg, New York, pp. 158-168, 2000.
22. Malaise EP, Lambin P and Joiner MC: Radiosensitivity of human cell lines to small doses. Are there some clinical implications? Radiat Res 138(1 Suppl): 25-27, 1994.